About the Company
We are a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging our proprietary Precision Cancer Monitoring® (PCM) technology and experience in tumor genomics.
Our broad intellectual property and proprietary technology allow us to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting patient response to cancer therapies.
We offer our PCM technology at our CLIA/CAP-accredited laboratory and plan to continue to vertically integrate our PCM technology with the development of precision cancer therapeutics. We believe our ctDNA PCM technology and expertise in liquid biopsy testing provides a unique advantage for the development of precision cancer therapeutics.
PCM-075: Our Lead Product Candidate
Our lead product candidate, PCM-075, was licensed from Nerviano Medical Sciences, S.r.l., a leading European oncology research and discovery organization, and is being developed for the treatment of patients with acute myeloid leukemia (AML).
PCM-075 is an oral and highly-selective polo-like kinase 1 (PLK1) inhibitor and allows us to leverage our PCM technology, and expertise in tumor genomics, to optimize the clinical development process, and uniquely positions us to bring a first-in-class PLK1 inhibitor to the market for the treatment of AML. We plan to leverage our technology and expertise to develop a PCM-075 AML biomarker panel to identify and measure patient response to therapy.
SAN DIEGO, Dec. 15, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the pricing of a public offering of 15,000,000 shares of its common stock (or common stock equivalents) and common warrants to purchase up to...
Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® for Metastatic Castration-Resistant Prostate Cancer
PCM-075, Trovagene’s Polo-like Kinase 1 (PLK1) inhibitor enhances activity of abiraterone in mCRPC tumor cells and may represent a novel combination treatment option in mCRPC SAN DIEGO, Dec. 14, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, engaged in...
Trovagene Announces the Launch of NextCollect™ Urine Collection and DNA Preservation Kit to Research Laboratories and Pharmaceutical Customers
SAN DIEGO, Dec. 12, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that its proprietary NextCollect™ urine collection and DNA preservation kit is now available, for research use only, to clinical research laboratories and pharmaceutical customers. ...
Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga® at San Antonio Breast Cancer Symposium (SABCS)
Targeted treatment with highly selective Polo-like Kinase 1 inhibitor, PCM-075, may represent a new option in TNBC, particularly in combination with other abiraterone acetate SAN DIEGO, Dec. 7, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced...